Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The research focuses on the use of biomarkers to diagnose Alzheimer’s disease (AD) in living individuals. Biomarkers for AD are grouped into Aβ deposition, pathologic tau, and neurodegeneration. Other potential candidates for AD, which include Neurofilament light (NEFL) protein, glial fibrillary acidic protein (GFAP), and growth differentiation factor 15 (GDF15), have been found in recent studies in addition to the Aβ and tau proteins. This review primarily addresses the methods used in the study, which was published in the journal Nature Aging, to measure biomarkers using fludeoxyglucose positron emission tomography, single molecule array, cerebospinal fluid sampling and blood proteomics, and dementia investigation to date. Inferred from the analysis, plasma proteins, NEFL, GFAP, and GDF15 were shown to be highly rated in protein significance ranking and to be most consistently linked with incident dementia and AD. An individual with greater GFAP levels is 2.32 times likely to acquire dementia. Early diagnosis is crucial for those with dementia, as it ensures that they receive the help and support they need. Furthermore, new drugs, such as donanemab and lecanemab, may be able to delay the progression of AD.

What this study adds

Evidence grade: Low

This review reports that plasma NEFL, GFAP and GDF15 were consistently linked with incident dementia and Alzheimer's, and that an individual with greater GFAP levels is 2.32 times likely to acquire dementia. It also notes that drugs such as donanemab and lecanemab may delay progression, but the review itself presents no new treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rajagopalan, R., Hariharan, S., Akshaya, N., & Senthamarai, R. (2025). A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer. Global Journal of Medical Pharmaceutical and Biomedical Update. https://doi.org/10.25259/gjmpbu_38_2024

Vancouver

Rajagopalan R, Hariharan S, Akshaya N, Senthamarai R. A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer. Global Journal of Medical Pharmaceutical and Biomedical Update. 2025. doi:10.25259/gjmpbu_38_2024.

BibTeX

@article{rajagopalan2025-5adb338a,
  author  = {Rajagopalan, Ramanathan and Hariharan, Sujatha and Akshaya, N.R. and Senthamarai, R.},
  title   = {{A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer}},
  journal = {Global Journal of Medical Pharmaceutical and Biomedical Update},
  year    = {2025},
  doi     = {10.25259/gjmpbu_38_2024},
  url     = {https://doi.org/10.25259/gjmpbu_38_2024}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review reports that plasma NEFL, GFAP and GDF15 were consistently linked with incident dementia and Alzheimer's, and that an individual with greater GFAP levels is 2.32 times likely to acquire dementia. It also notes that drugs such as donanemab and lecanemab may delay progression, but the review itself presents no new treatment or cure.

Study details

How this study scored 27/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 26 of the 97 points it could be judged on, which is 27 of 100. Total 27 of 100.26 of the 97 points we could judge = 27 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 26 of the 97 points we could judge it on, which is 27 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Global Journal of Medical Pharmaceutical and Biomedical Update)
Journal's citation record 0 / 4 Global Journal of Medical Pharmaceutical and Biomedical Update: journal h-index 8 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author R. Senthamarai: h-index 7 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 26 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 97 points we could judge it on is 27 out of 100.
Total 27 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Related studies in Biomarkers from nearby years

Also in Biomarkers

136 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →